Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Social security affiliation~* Written informed consent~* Histologically confirmed stage IV (M1a or M1b) non-small-cell lung cancer, including recurrent non-small-cell lung cancer after a period of complete remission~* D-dimer \> 1,500 µg/L~* First line of systemic cancer treatment (chemotherapy, immunotherapy or targeted therapy), or new line of systemic cancer treatment for cancer progression (chemotherapy, immunotherapy or targeted therapy), introduced during the month preceding inclusion or planned within one month after inclusion~* ECOG (Eastern Cooperative Oncology Group) score 0-2~* Life expectancy \>3 months~Exclusion Criteria:~* Hypersensitivity to heparin or to any excipients~* Septic endocarditis~* History of heparin-induced thrombocytopenia~* Ongoing anticoagulant treatment at therapeutic dosage~* VTE at inclusion~* Creatinin clearance \<30 mL/min~* Active bleeding~* Platelet count \< 100 G/L at inclusion~* Severe hepatic insufficiency~* Cancer treated exclusively with supportive care~* Aspirin at daily dosage \> 160 mg~* Pregnancy~* Patient under tutorship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): usual care,
- Experimental (Type: EXPERIMENTAL): tinzaparin sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).